The appointment went into effect on 1 November 2017. Kramers' teaching and research focuses on medication safety in the hospital setting. Medication errors are one of the biggest risks for hospitalised patients. It is estimated that half of these errors could be prevented through targeted education and supervision of prescribers. The chair therefore has a strong educational orientation.
Kramers is the first Professor of Medication Safety to be appointed in Nijmegen. In the past there has been a long time close collaboration between physicians and pharmacists in Nijmegen. This collaboration is a prerequisite for medication safety.
Kees Kramers (Dirksland, 1962) received his doctorate in Medicine from the University of Leiden in 1986. From 1989 until 1996 he was trained as an internist and from 1996 to 1998 as an internist-clinical pharmacologist, both at Radboud university medical center. In 1995 he obtained his PhD at Radboud University on research into antibodies that play a role in renal failure in the autoimmune disease systemic lupus erythematodes.
Training programmes in medication safety
Since 1989 Kramers has worked at Radboud university medical center on the staff of the Department of Pharmacology-Toxicology, and from 1998 he has also been on the staff of the Department of Internal Medicine, where he is responsible for patient care and teaching and research. Since 2010 he has been seconded to the Clinical Pharmacy Department at Canisius Willhelmina Hospital (CWZ) in Nijmegen.
In these roles he developed training programmes in medication safety for beginning physician assistants at Radboud university medical center and CWZ. He also chairs the Dutch Society for Clinical Pharmacology & Biopharmacy.
His recent achievements include the founding of the Nijmeegs Expertisecentrum voor Complexe Farmacotherapie (‘Nijmegen Expertise Centre for Complex Pharmacotherapy’), a regional partnership between hospital pharmacies, regional general practitioners and public pharmacists, and the development of a compulsory national pharmacotherapy exam for future physicians.
Related news items
Cognitive behavioral therapy effective in MD1 New treatment option for complex disease21 September 2018
Treatment with cognitive behavioral therapy helps patients with myotonic dystrophy type 1 in improving their physical abilities and social participation. This is the result of a survey of more than 250 patients in four European countries.read more
Rebecca Halbach receives poster prize at EMBO conference20 September 2018
Rebecca Halbach, theme Infectious diseases and global health, has received a poster prize at the EMBO Workshop ‘piRNAs and PIWI proteins’, held in Montpellier, France.read more
Netherlands X-omics Initiative: Consortium kick off meeting20 September 2018
The Netherlands X-omics Initiative had their consortium kick-off meeting. Consortium members from the Dutch partners involved gathered to get to know each other and to determine the next steps to start up the project.read more
Successful teamwork between Neurology and Human Genetics leads to identification of two new ataxia genes19 September 2018
Thanks to close cooperation between Bart van de Warrenburg (Neurology) and Erik-Jan Kamsteeg (Humans Genetics) two new genes involved in movement disorders were identified. The genes are relevant for autosomal recessive cerebellar ataxia.read more
Rectal cancer staging using MRI with endorectal filling19 September 2018
In the British Journal of Radiology Rutger Stijns and colleagues, showed that using MRI with endorectal filling did not lead to an improved rectal cancer staging and that it has the potential to influence the distance to a key anatomical landmark.read more